Back to top
more

Codexis (CDXS)

(Delayed Data from NSDQ)

$2.86 USD

2.86
738,589

-0.07 (-2.39%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $2.86 0.00 (0.00%) 7:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Vertex Pharmaceuticals (VRTX) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Vertex (VRTX) delivered earnings and revenue surprises of +6.60% and +2.59%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Regeneron (REGN) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Regeneron (REGN) delivered earnings and revenue surprises of +60.52% and +9.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Codexis (CDXS) delivered earnings and revenue surprises of -25% and 28.99%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Dare Bioscience (DARE) delivered earnings and revenue surprises of 20.63% and 95.83%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Immunome, Inc. (IMNM) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Immunome (IMNM) delivered earnings and revenue surprises of 21.21% and 28.33%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Codexis (CDXS) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Codexis (CDXS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

NovoCure (NVCR) delivered earnings and revenue surprises of 34.04% and 5.03%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Arcutis Biotherapeutics (ARQT) Moves 10.8% Higher: Will This Strength Last?

by Zacks Equity Research

Arcutis Biotherapeutics (ARQT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Codexis (CDXS) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Codexis (CDXS) delivered earnings and revenue surprises of -550% and 26.65%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Alkermes (ALKS) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Alkermes (ALKS) delivered earnings and revenue surprises of 28.40% and 13.56%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Codexis (CDXS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Codexis (CDXS) delivered earnings and revenue surprises of -16% and 10.27%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 7.4% Jump Turn into More Strength?

by Zacks Equity Research

Rhythm Pharmaceuticals (RYTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Codexis (CDXS) delivered earnings and revenue surprises of -23.08% and 4.51%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Codexis (CDXS) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Codexis (CDXS) delivered earnings and revenue surprises of 112.50% and 7.42%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Can Low Occupancy Rate Affect Select Medical (SEM) Q4 Earnings?

by Zacks Equity Research

Select Medical's (SEM) fourth-quarter results are likely to reflect growing visits in Outpatient Rehabilitation and Concentra.

Zacks Equity Research

ANSYS (ANSS) to Report Q4 Earnings: Here's What to Expect

by Zacks Equity Research

ANSYS' (ANSS) fourth-quarter performance is likely to have benefited from strength in the aerospace and defense, high-tech and automotive sectors.

Zacks Equity Research

WIX Set to Report Q4 Earnings: Here's What You Should Know

by Zacks Equity Research

WIX Q4 performance is likely to have benefited from an uptake of new products and improvement in the user base.

Zacks Equity Research

Higher Visits to Soften Cost Blow for Teladoc (TDOC) Q4 Earnings

by Zacks Equity Research

Teladoc's (TDOC) fourth-quarter results are likely to reflect growth in BetterHelp's profit levels.

Zacks Equity Research

Can Low Patient Days Affect Community Health (CYH) Q4 Earnings?

by Zacks Equity Research

Community Health's (CYH) fourth-quarter results are likely to reflect lower adjusted admissions, declining beds in services and occupancy rate.

Zacks Equity Research

Bristol Myers Squibb (BMY) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Bristol Myers (BMY) delivered earnings and revenue surprises of 13.64% and 0.28%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Codexis (CDXS) Transfers Leasing Rights to Vaxcyte, Stock Up

by Zacks Equity Research

Codexis (CDXS) transfers the leasing rights of its San Carlos, CA location to Vaxcyte to focus on technology development, inducing cost savings, to extend its cash runway to mid-2026. The stock rises 7%.

Zacks Equity Research

Codexis (CDXS) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Codexis (CDXS) delivered earnings and revenue surprises of 19.05% and 0.84%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Codexis (CDXS) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Codexis (CDXS) delivered earnings and revenue surprises of -17.24% and 11.34%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Alimera Sciences (ALIM) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Alimera Sciences (ALIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Codexis (CDXS) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Codexis (CDXS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.